Viatris/$VTRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viatris
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Ticker
$VTRS
Sector
Primary listing
Employees
32,000
Headquarters
Website
Viatris Metrics
BasicAdvanced
$11B
-
-$2.92
0.92
$0.48
5.02%
Price and volume
Market cap
$11B
Beta
0.92
52-week high
$13.35
52-week low
$6.85
Average daily volume
9.9M
Dividend rate
$0.48
Financial strength
Current ratio
1.37
Quick ratio
0.536
Long term debt to equity
82.153
Total debt to equity
92.947
Interest coverage (TTM)
3.02%
Profitability
EBITDA (TTM)
4,112.9
Gross margin (TTM)
40.86%
Net profit margin (TTM)
-24.57%
Operating margin (TTM)
10.90%
Effective tax rate (TTM)
7.51%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
2.26%
Return on equity (TTM)
-19.77%
Valuation
Price to revenue (TTM)
0.805
Price to book
0.72
Price to tangible book (TTM)
-1.49
Price to free cash flow (TTM)
6.701
Free cash flow yield (TTM)
14.92%
Free cash flow per share (TTM)
1.427
Dividend yield (TTM)
5.02%
Forward dividend yield
5.02%
Growth
Revenue change (TTM)
-7.37%
Earnings per share change (TTM)
438.86%
3-year revenue growth (CAGR)
-6.35%
10-year revenue growth (CAGR)
5.32%
3-year earnings per share growth (CAGR)
66.85%
10-year earnings per share growth (CAGR)
3.52%
3-year dividend per share growth (CAGR)
0.70%
What the Analysts think about Viatris
Analyst ratings (Buy, Hold, Sell) for Viatris stock.
Bulls say / Bears say
Viatris’ Q2 2025 revenue of $3.58 billion and adjusted EPS of $0.62 both surpassed consensus forecasts ($3.47 billion and $0.56 respectively), showing strong operational execution despite generic competition. (Reuters)
On a divestiture-adjusted operational basis, Q2 net sales rose 3%, driven by strong brand performance in Greater China and Emerging Markets, demonstrating Viatris’ diversified revenue streams. (Reuters)
Year-to-date through Q2, Viatris returned over $630 million to shareholders, including $350 million in stock buybacks, and reiterated $500 million–$650 million buyback guidance for 2025, highlighting robust free cash flow. (Reuters)
Viatris fell 11.3% in premarket trading after issuing 2025 revenue guidance of $13.5 billion–$14 billion, below the $14.27 billion analysts expected, and adjusted EPS guidance of $2.12–$2.26 versus a $2.59 consensus, highlighting growth challenges. (Reuters)
The company’s Q4 adjusted profit per share of $0.54 and sales of $3.52 billion missed estimates of $0.57 per share and $3.61 billion, pointing to operational headwinds. (Reuters)
The company estimates the FDA warning letter at its Indore facility will lower 2025 revenues by around $500 million and adjusted EBITDA by approximately $385 million, underscoring ongoing regulatory and supply chain risks. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Viatris Financial Performance
Revenues and expenses
Viatris Earnings Performance
Company profitability
Viatris News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viatris stock?
Viatris (VTRS) has a market cap of $11B as of September 17, 2025.
What is the P/E ratio for Viatris stock?
The price to earnings (P/E) ratio for Viatris (VTRS) stock is 0 as of September 17, 2025.
Does Viatris stock pay dividends?
Yes, the Viatris (VTRS) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is $0.48 and the yield is 5.02%. Viatris has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Viatris dividend payment date?
The next Viatris (VTRS) dividend payment date is unconfirmed.
What is the beta indicator for Viatris?
Viatris (VTRS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.